Nobivac KC
Active substance
ATC code
Species
Dogs.
Indications
Active immunisation of dogs against Bordetella bronchiseptica and canine parainfluenza virus for periods of increased risk to reduce clinical signs induced by B.
bronchiseptica and canine parainfluenza virus and to reduce shedding of canine parainfluenza virus.
|
Onset of immunity:
|
for Bordetella bronchiseptica: 72 hours after vaccination; for canine parainfluenza virus: 3 weeks after vaccination. |
|
Duration of immunity: |
1 year |
Dose to be administered and administration route
Nasal use.
Allow the sterile solvent provided to reach room temperature (15 °C – 25 °C). Aseptically reconstitute the lyophilisate with the solvent. Shake the vial well after addition of the solvent. Withdraw the vaccine into the syringe, remove the needle and administer 0.4 ml directly from the tip of the syringe into one nostril.
The reconstituted vaccine is an off-white or yellowish coloured suspension.
Vaccination scheme:
Dogs should be at least 3 weeks of age. When Nobivac KC is concurrently administered (i.e. not mixed) with another vaccine of the Nobivac series as indicated in section 4.8, dogs should not be younger than the minimum age recommended for the other Nobivac vaccine.
Unvaccinated dogs should receive one dose at least 3 weeks prior to the period of anticipated risk, e.g. temporary kennelling, in order to get protection for both vaccine agents. In order to get protection for Bordetella bronchiseptica unvaccinated dogs should receive one dose at least 72 hours prior to the period of anticipated risk (see also section 4.5 ‘Special precautions for use’).
Revaccinate annually.
Adverse reactions
In laboratory studies and field trials:
Mild discharges from the eyes and nose have been observed very commonly from the day after vaccination, sometimes accompanied by wheezing, sneezing and/or coughing, particularly in very young susceptible puppies. Signs are generally transient, but in occasional cases may persist for up to four weeks. In animals, which show more severe signs, appropriate antibiotic treatment may be indicated.
In post marketing experience:
Lethargy and vomiting may occur after vaccination in very rare cases.
Hypersensitivity reactions may occur in very rare cases. Such reactions may evolve to a more severe condition (anaphylaxis), which may be life-threatening. If such reactions occur appropriate treatment is recommended.
Clinical signs of immune-mediated haemolytic anaemia, immune-mediated thrombocytopenia or immune-mediated polyarthritis have been reported in very rare cases.
The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports)
